With the advent of Imatinib, tremendous progress has been made in the treatment of patients with GIST.
Dr. Brian Rubin I’ve been working on a cure for GIST most of my professional life and the initial work was both exciting and fulfilling. I remember when we confirmed the presence [...]
Members of the Life Raft Group Research Team continue to publish results of promising studies aimed at finding a cure for GIST. The latest reflects the collaboration that guides its efforts.
A study about the DREAM complex was published in the June issue of Cancer Research by LRG Research Team members Drs. Anette Duensing and Maria Debiec-Rychter.
During the past dozen years gastrointestinal stromal tumors have emerged from oncologic obscurity and reached center-stage in the development of targeted therapies for solid tumors. Tyrosine kinase inhibitors (TKIs) like imatinib, sunitinib, and more recently regorafenib, have proven effective in suppressing the growth of metastatic GIST, allowing patients to live far longer than during the previous era of ineffective chemotherapy.
Breaking Research Barriers! The Life Raft Group Research Team is unique. As we know, the purpose of research is to inform, educate and allow us to live better lives.
Time magazine this month published an in-depth look at how collaboration is beginning to change the way cancer research is approached, citing numerous examples of the effectiveness of scientists working together to find a cure.
The Food and Drug Administration, in a much-anticipated announcement for Gastrointestinal Stromal Tumor patients, approved Bayer Pharmaceutical’s drug, Stivarga, for use as a third-line treatment for advanced GIST in February.
If you have been mailed a fundraising packet and still have donor cards to send out, it is not too late. Consider passing one on to a neighbor co-worker, friend or family member.
The LRG Research Team recently held a teleconference that focused primarily on a study the team will collaborate on and intends to publish.